drugset
drugset / Trial / NCT04705883

Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors

NCT04705883 ↗

Phase 4 Completed 10 enrolled Hospital Clinic of Barcelona
NaSingle-groupOpen-labelOther

Summary

VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)

Timeline

Start
2020-09-01
Primary completion
2021-11-08
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified 6.5 mg Other

Indications

breast cancer postmenopausal atrophic vaginitis